Grant: Discovery Horizons
McMaster University
$100,000.00
Reprogramming lung macrophages using inhalable immunomodulatory microparticles for the treatment of lung fibrosis
EF 2024-25
Résumé
While most current strategies for treating disease aim to reduce inflammation levels at the disease site, emerging evidence is suggesting that this is not always necessary or even beneficial for treating many diseases. One such disease is idiopathic pulmonary fibrosis (IPF), a disease that affects >14,000 Canadians with a four-year risk of death of 41%. In IPF, a key cell involved in the inflammatory process (a macrophage) is "reprogrammed" to instead produce scar tissue, resulting in a significant decrease in lung elasticity and thus breathing difficulties. While two drugs are available for treating IPF, they have significant side-effects and typically can only slow further progression of the disease. As such, developing a new approach to reprogram macrophages to an anti-fibrosis state (avoiding scar tissue formation) using a therapeutic that can be locally delivered into the lungs (avoiding off-target side effects) offers potential to not only slow but potentially reverse lung fibrosis.
In this project, the highly interdisciplinary team of Todd Hoare (applied biomedical materials), Ryan Wylie (targeted drug delivery), Dawn Bowdish (macrophage biology) and Martin Kolb (clinical respirology) will address this challenge by developing inhalable microparticles that can directly reprogram macrophages only in the lung while avoiding the need for expensive or hard-to-store biological therapeutics. In particular, we will design a suite of new materials that bind to specific surface proteins on pro-fibrosis macrophages and either reprogram them back to an anti-fibrosis state, kill them specifically (leaving other "useful" macrophages unaffected), or both. Microparticles that can successfully alter macrophage biology and be inhaled using commercial devices (e.g. an asthma puffer) will be tested on precision cut lung slices from diseased and healthy human lungs, with materials showing efficacy then tested in a mouse model of fibrosis. We anticipate identifying at least one inhalable microparticle formulation that can suppress the pro-fibrosis activity of macrophages over at least one day (minimizing re-administration frequencies), with the aim to patent and commercialize the new formulation(s) with existing or emerging industry partners. In addition, the materials-only nature of our proposed technology would enable the formulation to remain stable without requiring specific cold storage conditions, key to reducing healthcare access barriers in remote communities.
Programme
Discovery Horizons
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
DH-2023-00635
Name nom
Hoare, Todd
Department département
Chemical Engineering - McMaster University
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2023
Award amount
100000
Program id
DH
Program name en
Discovery Horizons
Program name fr
Horizons de la découverte
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
nan
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Field of research list codes
RDF3010506
Field of research list names en
Drug discovery, design and delivery
Field of research list names fr
Découverte, conception et administration de médicaments
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Reprogramming lung macrophages using inhalable immunomodulatory microparticles for the treatment of lung fibrosis
Keywords
lung fibrosis; inhalation; microparticles; immunomodulatory materials; macrophage reprogramming; drug delivery; biomaterials
Application summary
While most current strategies for treating disease aim to reduce inflammation levels at the disease site, emerging evidence is suggesting that this is not always necessary or even beneficial for treating many diseases. One such disease is idiopathic pulmonary fibrosis (IPF), a disease that affects >14,000 Canadians with a four-year risk of death of 41%. In IPF, a key cell involved in the inflammatory process (a macrophage) is "reprogrammed" to instead produce scar tissue, resulting in a significant decrease in lung elasticity and thus breathing difficulties. While two drugs are available for treating IPF, they have significant side-effects and typically can only slow further progression of the disease. As such, developing a new approach to reprogram macrophages to an anti-fibrosis state (avoiding scar tissue formation) using a therapeutic that can be locally delivered into the lungs (avoiding off-target side effects) offers potential to not only slow but potentially reverse lung fibrosis.
In this project, the highly interdisciplinary team of Todd Hoare (applied biomedical materials), Ryan Wylie (targeted drug delivery), Dawn Bowdish (macrophage biology) and Martin Kolb (clinical respirology) will address this challenge by developing inhalable microparticles that can directly reprogram macrophages only in the lung while avoiding the need for expensive or hard-to-store biological therapeutics. In particular, we will design a suite of new materials that bind to specific surface proteins on pro-fibrosis macrophages and either reprogram them back to an anti-fibrosis state, kill them specifically (leaving other "useful" macrophages unaffected), or both. Microparticles that can successfully alter macrophage biology and be inhaled using commercial devices (e.g. an asthma puffer) will be tested on precision cut lung slices from diseased and healthy human lungs, with materials showing efficacy then tested in a mouse model of fibrosis. We anticipate identifying at least one inhalable microparticle formulation that can suppress the pro-fibrosis activity of macrophages over at least one day (minimizing re-administration frequencies), with the aim to patent and commercialize the new formulation(s) with existing or emerging industry partners. In addition, the materials-only nature of our proposed technology would enable the formulation to remain stable without requiring specific cold storage conditions, key to reducing healthcare access barriers in remote communities.